The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in
November 2019, quickly spread around the world becoming a pandemic. Despite the …

Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-
2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease …

The nucleotide analogue prodrug remdesivir remains the only FDA-approved antiviral small
molecule for the treatment of infection with SARS-CoV-2. Biochemical studies revealed that …

The rapid spread of the virus, the surge in the number of deaths, and the unavailability of
specific SARS-CoV-2 drugs thus far necessitate the identification of drugs with anti-COVID …

The coronavirus disease-2019 (COVID-19) pandemic continues to challenge health care
systems around the world. Scientists and pharmaceutical companies have promptly …

Human coronaviruses (HCoV) were discovered in the 1960s and were originally thought to
cause only mild upper respiratory tract diseases in immunocompetent hosts. This view …

Introduction: Remdesivir, an experimental antiviral drug has shown to inhibit severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), both in vitro and in vivo. The present …

An acute respiratory disease caused by a novel coronavirus [severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus …

If a planned path reaches a dead-end, one can simply stop. Or one can turn around, walk
back to the last intersection and take another path, or one can consider taking few paths in …

Abstract Remdesivir (RDV, Veklury®) is a once-daily, nucleoside ribonucleic acid
polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 replication …